Skip to main content

Associate Professor of Medicine

Associate Professor of Medicine, Division of Pulmonary Diseases and Critical Care Medicine

Specialty Areas (clinical or research areas of expertise): Interstitial Lung Disease, Critical Care Medicine

Chronology (Education and employment. Chronological order. Employment chronology can begin after MD): BS Summa Cum Laude: West Virginia Wesleyan College, 1996, MD Magna Cum Laude: Emory University School of Medicine, 2000, Internship and Residency: University of California, San Francisco 2000-2003, Chief Medical Residency: University of California, San Francisco 2003-2004, Pulmonary and Critical Care Fellowship: University of California, San Francisco 2004-2007, Assistant Professor of Medicine: University of Cincinnati College of Medicine 2007-2011, MS Clinical Research: University of Cincinnati College of Medicine 2011, Staff Physician, Mercy Health Physicians, Cincinnati, Ohio 2011-2021, Clinical Associate Professor of Medicine, University of North Carolina 2021-present

Description of research and/or clinical interests. Dr. Kinder’s clinical interests include the diagnosis and management of intersititial lung diseases (ILD) and critical care medicine. Dr. Kinder’s research focus includes interstitial lung disease and the overlap with rheumatologic diseases and clinical trials of novel therapeutics in ILD.

Selected Bibliography (reverse chronological order).

McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH, Strange C, Seyama K, Sullivan EJ, Kotloff RM, Downey GP, Chapman JT, Han MK, D’Armiento JM, Inoue Y, Henske EP, Bissler JJ, Colby TV, Kinder BW, Wikenheiser-Brokamp KA, Brown KK, Cordier JF, Meyer C, Cottin V, Brozek JL, Smith K, Wilson KC, Moss J; Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. ATS/JRS Committee on Lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2016 Sep 15;194(6):748-61

Couluris M, Kinder BW, Xu P, Gross-King M, Krischer J, Panos RJ. Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. Lung. 2012 Oct;190(5):523-7. Epub 2012 Jul 19.

Oprescu N, McCormack FX, Byrnes S, Kinder BW. Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry. Lung. 2013 Feb;191(1):35-42. doi: 10.1007/s00408-012-9419-3. Epub 2012 Sep 25.

Kinder BW. Nonspecific interstitial pneumonia. Clin Chest Med. 2012 Mar;33(1):111-21

McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011 Apr 28;364(17):1595-606. Epub 2011 Mar 16.

Hagaman JT, Panos RJ, McCormack FX, Thakar CV, Wikenheiser-Brokamp KA, Shipley RT, Kinder BW. Vitamin D deficiency and reduced lung function in connective tissue-associated interstitial lung diseases. Chest. 2011 Feb;139(2):353-60. Epub 2010 Aug 5.

Young LR, VanDyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, W. Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ , Franz DN, and FX McCormack. 2010. Serum Vascular Endothelial Growth Factor-D Prospectively 1 Distinguishes Lymphangioleiomyomatosis from Other Diseases. Chest. 2010 Sep;138(3):674-81.

Hagaman, JT, DP Schauer, F X McCormack, and BW Kinder. 2010. Screening for Lymphangioleiomyomatosis with High-Resolution CT in Young, Nonsmoking Women Presenting With Spontaneous Pneumothorax is Cost-Effective. Am J Respir Crit Care Med. Feb18.

Kinder, BW, Shariat C, Collard HR, Koth LL, Wolters PJ, Golden JA, Panos RJ, King TE Jr. Undifferentiated Connective Tissue Disease-Associated Interstitial Lung Disease: Changes in Lung Function. Lung. 2010 Jan 14.

Hagaman, JT, BW Kinder and MH Eckman. Thiopurine S-Methyltranferase Testing in Idiopathic Pulmonary Fibrosis: A Pharmacogenetic Cost-Effectiveness Analysis. Lung. 2010 Jan 12.

Kinder, BW, A. C. Sherman, L. R. Young, J. T. Hagaman, N. Oprescu, S. Byrnes, and F. X. McCormack. 2009. Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis. Respir Med. 2009. Dec 3.

Kinder, BW, Brown, K.K., McCormack F.X., Ix J.I., Kervitsky A., Schwarz M.I., King, T.E. Jr. 2009. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009 Mar 2.

Kinder BW, Brown KK, Schwarz MI, Ix JI, Kervitsky A, and King TE Jr.: Baseline bronchoalveolar lavage neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest. 2008. 133(1): p. 226-32. Epub Dec 10. 2007.

Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD , and King TE Jr.: Idiopathic Nonspecific Interstitial Pneumonia: Lung manifestation of Undifferentiated Connective Tissue Disease?. American Journal of Respiratory and Critical Care Medicine. Oct 1; 176(7):691-7. Epub 2007 Jun 7.

Kinder BW, Freemer MM, King TE Jr., Lum RF, Nititham J, Taylor K, Edberg J, Bridges SL Jr., and Criswell LA: Clinical and Genetic risk factors for pneumonia in SLE. Arthritis and Rheumatism. 2007 Jul 30;56(8):2679-2686

Brent Kinder